Health Utility Values Measured by EQ-5D in Breast Cancer From Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis Protocol [0.03%]
发展中国家乳腺癌患者EQ-5D健康效用值的系统评价和 meta分析方案
Lynn Jia Tay,Siew Chin Ong,Lyn Xuan Tay
Lynn Jia Tay
Background: Health utility values (HUVs) are fundamental parameters in economic evaluations used to assess the value of healthcare interventions. However, patients living with breast cancer in low- and middle-income count...
Budget Impact Analysis of Vacuum-Assisted Excision Versus Surgical Excision for the Assessment of Breast Lesions of Uncertain Malignant Potential in Italy [0.03%]
意大利不确定恶性潜能乳腺病变的真空辅助切除与手术切除的预算影响分析
Carla Rognoni,Ludovico Cavallaro,Gaia Grassi et al.
Carla Rognoni et al.
Background/objective: B3 breast lesions, of uncertain malignant potential, pose diagnostic challenges owing to their intermediate malignancy risk. While surgical excision (SE) is traditionally used for definitive diagnosi...
A Micro-costing Study of Community-Based Primary HPV Self-Sampling and Triage Test for Cervical Cancer Screening in Rural Cambodia [0.03%]
柬埔寨农村基于社区的HPV自取样及分流检测用于宫颈癌筛查的微成本研究
Ziyue Zhang,Hermann Bussmann,Sathiarany Vong et al.
Ziyue Zhang et al.
Background: Community-based human papillomavirus (HPV) self-sampling can expand cervical cancer screening coverage in rural settings, but local programmatic cost evidence is limited. ...
Prediction Error in Quality-Adjusted Life Years in Economic Evaluations of Immune Checkpoint Inhibitors: A Comparison Based on Projected and Observed Updated Survival [0.03%]
基于预期和观察更新生存率的免疫检查点抑制剂经济评估中质量调整生命年的预测误差比较分析
Jinyu Chen,Yichen Zhang,Kexin Han et al.
Jinyu Chen et al.
Background: Survival data from pivotal clinical trials are critical for estimating quality-adjusted life years (QALYs). However, immature survival data require extrapolation beyond observed follow-up to project outcomes, ...
Validation of the Obesity Lifecycle Model Built to Assess the Cost Effectiveness of Novel Therapies in the Management of Obesity [0.03%]
肥胖生命历程模型的有效性研究——评估新型疗法在肥胖症管理中的成本效益分析模型
Ben Modley,Ahmed Seddik,Marc Evans et al.
Ben Modley et al.
Background: Economic models support healthcare decision makers to efficiently assess value and allocate resources; formal validation is critical to ensure confidence in model outputs. The Obesity Lifecycle Model is a pati...
Adverse Drug Reaction Costs and Study Quality in Africa: A Systematic Review of Cost-of-Illness Studies [0.03%]
非洲药品不良反应的成本及研究质量：成本疾病负担系统评价
Bezie Kebede,Bereket Bahiru,Chernet Tafere
Bezie Kebede
Objective: An adverse drug reaction (ADR) is a harmful, unwanted patient response to a drug that happens at doses normally used for prevention, diagnosis, or treatment. Despite limited and inconsistent primary evidence on...
Economic Burden of Spinal Muscular Atrophy in Singapore: A Societal Perspective Cost-of-Illness Study [0.03%]
新加坡脊髓性肌萎缩症的经济负担——一项从社会角度出发的成本-疾病研究
Zhi Zhen Lim,Yan Ling Lim,Furene Sijia Wang et al.
Zhi Zhen Lim et al.
Objectives: The objective was to evaluate the overall economic burden of spinal muscular atrophy (SMA) in Singapore. Methods: A retrosp...
Estimating Eligibility for Lung Cancer Screening in Ireland: A Dynamic Modelling Study of Smoking Trends [0.03%]
爱尔兰肺癌筛查资格评估：吸烟趋势动态模型研究
Tatiana Bezdenezhnykh,James F O&#x;Mahony,Benjamin M Jacob et al.
Tatiana Bezdenezhnykh et al.
Background: Lung cancer screening (LCS) with low-dose computed tomography (LDCT) reduces mortality. Ireland will likely adopt a national screening programme in the coming years, and evidence on the size of the eligible po...
Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities from a Targeted Literature Review and Expert Workshop [0.03%]
基于目标文献回顾和专家研讨会的经济学评价中关于损失生产力测量发展的证据优先级
R Brett McQueen,Benjamin Cohen,Caroline Kacergis et al.
R Brett McQueen et al.
Background: Productivity losses from illness, treatment, and informal caregiving impose a substantial economic burden on patients, caregivers, employers, and society in the United States (US), but measurement remains inco...
Correction: Cost-Effectiveness Analysis of Sequential Treatment Strategies for Moderate to Severe Crohn's Disease in Spain: Where Should Biosimilar Ustekinumab Be Positioned? [0.03%]
Correction: Spain的成本效益分析：中重度克罗恩病序贯治疗策略的经济学分析：生物类似物乌司奴单抗应处于什么位置？
Iago Rodríguez-Lago,José Ignacio Peinado-Fabregat,Marcelo Guigini et al.
Iago Rodríguez-Lago et al.
Published Erratum
PharmacoEconomics - open. 2026 Apr 21. DOI:10.1007/s41669-026-00648-9 2026